EcuadorTuberculosis profile
Population  2016 16 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.4 (0.31–0.49) 2.4 (1.9–3)
Mortality (HIV+TB only) 0.34 (0.22–0.49) 2.1 (1.3–3)
Incidence  (includes HIV+TB) 8.2 (5.3–12) 50 (33–72)
Incidence (HIV+TB only) 1.1 (0.69–1.5) 6.5 (4.2–9.2)
Incidence (MDR/RR-TB)** 0.71 (0.43–1) 4.4 (2.6–6.1)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.47 (0.29–0.66) 2.6 (1.6–3.6) 3.1 (1.9–4.3)
Males 0.49 (0.3–0.69) 4.7 (2.9–6.5) 5.2 (3.2–7.2)
Total 0.97 (0.59–1.3) 7.3 (4.4–10) 8.2 (5.3–12)
TB case notifications, 2016  
Total cases notified 5 374
Total new and relapse 5 284
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 89%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 91%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 64% (45–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.09 (0.06–0.14)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 636 13%
          - on antiretroviral therapy 583 92%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  370
(290–450)
Estimated % of TB cases with MDR/RR-TB 7.3% (5.4–9.2) 28% (25–31)  
% notified tested for rifampicin resistance     948
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 160, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 155, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 77% 5 097
Previously treated cases, excluding relapse, registered in 2015 51% 118
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 50% 120
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 6%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 1.7
Funding source: 100% domestic,  international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data